Biotech News

Protagenic Therapeutics Receives $3.1 Million from Recent Warrant Activity

Protagenic Therapeutics (PTIX)Protagenic Therapeutics2025-05-21 09:15 ESTCompany update

NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") announced today that warrant exchanges and exercises over the last four trading days have generated $3.1 million in cash. The proceeds will fund working-capital needs and advance the Company's peptide-based drug candidates for stress-related and...

Related news

IKTInhibikase Therapeutics2026-08-11 20:01 EST

Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity

IKTInhibikase Therapeutics2026-07-14 12:00 EST

Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility

KTTAPasithea Therapeutics2026-06-30 11:00 EST

Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion

GANXGain Therapeutics2026-06-29 20:05 EST

Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease

DNLIDenali Therapeutics2026-06-18 12:00 EST

Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million

GANXGain Therapeutics2026-08-11 11:00 EST

Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update

AXSMAxsome2026-08-10 11:00 EST

Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

CGTXCognition Therapeutics2026-08-06 20:15 EST

Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update

DNLIDenali Therapeutics2026-08-06 20:01 EST

Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

KTTAPasithea Therapeutics2026-07-21 11:00 EST

Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026

View all latest news

Protagenic Therapeutics

Protagenic Therapeutics is a biotechnology company focused on neuropsychiatric and stress-related disorders. Its story is built around the idea that peptide-based or related approaches can address difficult CNS conditions.

Recent company news

PTIXProtagenic Therapeutics2026-05-19 08:15 EST

Protagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partner

PTIXProtagenic Therapeutics2026-04-23 08:15 EST

Protagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114

PTIXProtagenic Therapeutics2026-03-17 08:00 EST

Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114

PTIXProtagenic Therapeutics2026-03-10 08:00 EST

Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market

PTIXProtagenic Therapeutics2025-12-09 08:46 EST

Results from Phase 1 Multiple-Dose Study of PT00114

Stock data

Close: 0.80 USD
Market cap: —
Exchange: NASDAQ
Sector: Biopharma
Location: United States